Anavex Life Sciences (NASDAQ: AVXL) is a clinical-stage biopharmaceutical company engaged in the development of drug candidates for the treatment of pain, Alzheimer’s disease, other central nervous system diseases, and various cancers. The company’s lead drug candidates include ANAVEX 2-73, a phase IIa clinical trial for the treatment of Alzheimer’s disease; also in preclinical stage … Continue reading “Anavex Life Sciences Corp. (NASDAQ: AVXL) Starts Presentation at NobleCon13”
Sangamo Therapeutics (NASDAQ: SGMO) is trading higher this morning on news the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s SB-318, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare lysosomal storage disorder. The FDA grants orphan drug designation to drugs and … Continue reading “NetworkNewsBreaks – Sangamo Therapeutics, Inc. (NASDAQ: SGMO): FDA Grants Orphan Drug Designation for SB-318”
Shares of Anavex Life Sciences (NASDAQ: AVXL) are higher after the company said its ANAVEX 2-73 candidate met primary and secondary endpoints in a phase 2a study of patients with mild-to-moderate Alzheimer’s disease (AD). ANAVEX 2-73 was well tolerated and there were no clinically significant treatment-related adverse events and no serious adverse events. Despite non-optimized … Continue reading “NetworkNewsBreaks – Anavex Life Sciences (AVXL) Releases Positive Data for ANAVEX 2-73 in Alzheimer’s Study; Trading Higher”
GSI Technology (NASDAQ: GSIT) is a fabless semiconductor company that designs, develops and markets memory products primarily for the networking and telecommunications markets. It offers synchronous static random access memory (SRAM) products, such as BurstRAMs for microprocessor cache applications; No Bus Turnaround SRAMs to address the needs of moderate performance networking applications; and SigmaQuad and … Continue reading “GSI Technology (GSIT) Starts Presentation at LD Micro Main Event”
Anavex Life Sciences (NASDAQ: AVXL) this morning issued a positive update from its phase 2a study of ANAVEX 2-73 in patients with mild-to-moderate Alzheimer’s disease. At 41 weeks, Alzheimer’s patients showed a stabilization of cognitive and functional measures taking a daily oral dosing between 10mg and 50mg of ANAVEX 2-73 in the exploratory clinical trial. … Continue reading “NetworkNewsBreaks – Anavex Life Sciences (AVXL) Reports Positive Data for ANAVEX 2-73 in Patients with Alzheimer’s; Shares Higher”
Anavex Life Sciences (NASDAQ: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, this morning announced its collaboration with Ariana Pharma (Cambridge, MA and Paris, France) in which Anavex will use Ariana’s proprietary, FDA-tested KEM® (Knowledge, Extraction, Management) patient stratification technology to potentially accelerate ANAVEX 2-73’s ongoing phase … Continue reading “Anavex Life Sciences Corp. (AVXL) Teams with Ariana Pharma to Advance Alzheimer’s and Parkinson’s Clinical Development Programs”
At the World Parkinson Congress 2016 in Portland earlier today, Anavex Life Sciences (NASDAQ: AVXL) presented preclinical data in a poster titled “Investigating the potential neurorestorative effects of a clinical Sigma-1 receptor agonist in a mouse model of Parkinson’s disease.” Initial data demonstrated that the company’s ANAVEX 2-73, a sigma-1 receptor agonist, restores function in … Continue reading “Anavex Life Sciences Corp. (AVXL) Presents Positive Initial Data for Parkinson’s Disease Drug Candidate”
